MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Certara Inc

Gesloten

SectorGezondheidszorg

9.99 -1.28

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.88

Max

10

Belangrijke statistieken

By Trading Economics

Inkomsten

3.5M

1.5M

Verkoop

46K

105M

K/W

Sectorgemiddelde

135.857

89.037

Winstmarge

1.458

Werknemers

1,487

EBITDA

-6.5M

23M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+21.1% upside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-365M

1.5B

Vorige openingsprijs

11.27

Vorige sluitingsprijs

9.99

Nieuwssentiment

By Acuity

50%

50%

142 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Certara Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jan 2026, 18:41 UTC

Winsten

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24 jan 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

24 jan 2026, 06:18 UTC

Acquisities, Fusies, Overnames

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 jan 2026, 22:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 jan 2026, 22:30 UTC

Marktinformatie

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 jan 2026, 22:03 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 21:52 UTC

Winsten
Acquisities, Fusies, Overnames

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

23 jan 2026, 21:39 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 jan 2026, 21:12 UTC

Winsten

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 jan 2026, 20:31 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 20:12 UTC

Marktinformatie

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 jan 2026, 20:07 UTC

Marktinformatie

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 jan 2026, 19:36 UTC

Marktinformatie

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 jan 2026, 19:30 UTC

Marktinformatie
Winsten

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 jan 2026, 19:18 UTC

Marktinformatie

Gold and Silver Step Up to More Records -- Market Talk

23 jan 2026, 19:15 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23 jan 2026, 18:53 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23 jan 2026, 18:21 UTC

Winsten

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23 jan 2026, 18:19 UTC

Marktinformatie

Intel Seen as Increasingly Confident on Demand -- Market Talk

23 jan 2026, 17:59 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23 jan 2026, 17:57 UTC

Marktinformatie

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23 jan 2026, 17:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Certara Inc Prognose

Koersdoel

By TipRanks

21.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12.11 USD  21.1%

Hoogste 16 USD

Laagste 9 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Certara Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technische score

By Trading Central

11.27 / 12.79Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

142 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat